Smart Immune
Created in 2017
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
5,807Activities
Technologies
Entity types
Location
Faculté de Médecine - Site Cochin, 24 Rue du Faubourg Saint-Jacques, 75014 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 35
Engaged corporates
24
12 14Added in Motherbase
1 year, 8 months ago
biotech Value proposition
Pioneering thymus-empowered T-cell platform to fight cancer and infection
Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted treatments like off-the-shelf CAR T. The Company is headquartered in Paris, France, at Paris Biotech Santé.
Biotechnology, Cell therapy, CAR T, Immuno-oncology, NK cells, T cells, Immune reconstitution, T cell progenitors, Lymphoid progenitors, Naive cells, HSC differentiation, and Thymic selectionOriginal language
Pioneering thymus-empowered T-cell platform to fight cancer and infection
Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted treatments like off-the-shelf CAR T. The Company is headquartered in Paris, France, at Paris Biotech Santé.
Unlocking the power of allogeneic T-cell therapies to fight cancer and infection
Smart Immune is a clinical-stage biotechnology company developing ProTcell a thymus-empowered cell therapy platform to fully and rapidly re-arm the immune system against cancers and infections.
https://www.smart-immune.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 8 Jun 2023 | | |
 NEFTYS Finance, Financial Services | NEFTYS Finance, Financial Services | Other 12 May 2023 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 19 Mar 2024 | | |
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 3 Jul 2023 | | |
 Le Figaro Media, Newspaper Publishing | Le Figaro Media, Newspaper Publishing | Other 22 Mar 2024 | | |
 Financial Times Media, Newspaper Publishing | Financial Times Media, Newspaper Publishing | Other 19 Apr 2023 | | |
 WILCO Software Development | WILCO Software Development | Other 3 Apr 2023 | | |
 La French Tech Grand Paris French Tech, IT Services and IT Consulting | La French Tech Grand Paris French Tech, IT Services and IT Consulting | Other 27 Mar 2023 | | |
 La French Tech Lille French Tech, IT Services and IT Consulting | La French Tech Lille French Tech, IT Services and IT Consulting | Other 27 Mar 2023 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 12 Feb 2024 | | |